Insulin Degludec (Tresiba) Dosing
For insulin-naïve adults with type 2 diabetes, start insulin degludec at 10 units once daily, then titrate by 2 units every 3-4 days based on fasting plasma glucose to reach your individualized glycemic target without hypoglycemia. 1
Starting Doses
Type 2 Diabetes (Insulin-Naïve)
- Start at 10 units once daily 1
- Alternative approach: 0.1-0.2 units/kg/day 2
- Can be administered at any time of day in adults (flexibility is a key advantage of degludec) 1
Type 1 Diabetes (Insulin-Naïve)
- Start at one-third to one-half of total daily insulin requirement 1
- Calculate total daily insulin as 0.2-0.4 units/kg body weight 1
- Remainder must be given as short-acting insulin divided among meals 1
- Critical caveat: Degludec MUST be used with short-acting insulin in type 1 diabetes 1
Pediatric Patients (≥1 year old)
- Must dose at the same time every day (unlike adults who have dosing flexibility) 1
- When switching from other basal insulins: start at 80% of previous basal insulin dose to minimize hypoglycemia risk 1
Titration Protocol
Increase dose by 2 units every 3-4 days until fasting plasma glucose reaches target (typically 80-130 mg/dL) 2, 1. The FDA label explicitly states 3-4 days between adjustments 1, which aligns with the 2025 ADA Standards recommending increases every 3 days 2.
Alternative titration approaches from clinical trials:
- Simple algorithm: adjust based on single pre-breakfast glucose measurement 3
- Step-wise algorithm: adjust based on three consecutive pre-breakfast values 3
- Both approaches achieved similar glycemic control (HbA1c reduction ~1%) 3
For hypoglycemia: Identify the cause; if no clear reason exists, reduce dose by 10-20% 2
Conversion from Other Basal Insulins
Adults (Type 1 or Type 2)
Switch unit-for-unit from total daily long- or intermediate-acting insulin dose 1. Real-world data suggests:
- From once-daily glargine/detemir: Degludec dose = 3.39 + (0.78 × previous dose) 4
- From twice-daily glargine/detemir: Degludec dose = 0.44 + (0.69 × previous dose) 4
Pediatric Patients
Start at 80% of previous basal insulin dose to reduce hypoglycemia risk 1
High-Dose Conversions
When switching from basal insulin doses of 40-50 units/day, expect a transient increase in fasting glucose during week 1 (mean +1.1 mmol/L), which normalizes by week 4 without clinical consequence 5. Continue titration as planned.
Missed Dose Management
Adults
- Inject during waking hours upon discovery 1
- Ensure at least 8 hours between consecutive injections 1
- This flexibility is unique to degludec's ultra-long duration of action
Pediatric Patients
- Contact healthcare provider for guidance 1
- Monitor blood glucose more frequently until next scheduled dose 1
Available Formulations
- U-100: FlexTouch pen (1-unit increments, max 80 units/injection) or 10 mL vial 1
- U-200: FlexTouch pen (2-unit increments, max 160 units/injection) 1
- No dose conversion needed between concentrations—the pen displays actual units to deliver 1
Key Clinical Considerations
Avoid overbasalization: If fasting glucose remains elevated despite doses approaching 0.5-1.0 units/kg/day, do not continue escalating basal insulin 6. Instead, add prandial insulin or intensify other glucose-lowering therapies 2, 6.
Typical maintenance doses: Clinical trials show mean doses of 0.59-0.61 units/kg in type 2 diabetes 7 and up to 1.3 units/kg in complex cases 8.
Hypoglycemia advantage: Degludec demonstrates significantly lower nocturnal hypoglycemia rates compared to glargine (0.25 vs 0.39 episodes/patient-year) 7, making it particularly suitable for patients at high hypoglycemia risk.
Dosing flexibility: The ultra-long half-life permits flexible once-daily dosing at varying times in adults 9, which may improve adherence in patients with unpredictable schedules.